4.7 Review

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Journal

JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 14, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13045-021-01083-5

Keywords

Cancer immunotherapy; Adoptive cell therapy; Chimeric antigen receptor; Natural killer cells; Genetic modification

Funding

  1. China Scholarship Council (CSC) [201707720056]
  2. Kootstra Talent Fellowship (Maastricht University)
  3. Marie Sklodowska-Curie Individual fellowship (European Union) [799810-TOPNIN]
  4. Cancer Research Institute/Irvington Postdoctoral Fellowship
  5. la Caixa Foundation [100010434, LCF/BQ/PR20/11770004]
  6. Cancer Research Foundation Limburg [2012-03 KOFL]
  7. GROW School of Maastricht University

Ask authors/readers for more resources

NK cells, especially CAR-NK cells, play a crucial role in cancer treatment. Advances in CAR-NK technology show promising potential in efficiently targeting cancer cells with reduced side effects. These developments contribute to improving cancer treatment strategies.
Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are considered as specialized immune cells that can be genetically modified to obtain capable effector cells for adoptive cellular treatment of cancer patients. However, biological and technical hurdles related to gene delivery into NK cells have dramatically restrained progress. Recent technological advancements, including improved cell expansion techniques, chimeric antigen receptors (CAR), CRISPR/Cas9 gene editing and enhanced viral transduction and electroporation, have endowed comprehensive generation and characterization of genetically modified NK cells. These promising developments assist scientists and physicians to design better applications of NK cells in clinical therapy. Notably, redirecting NK cells using CARs holds important promise for cancer immunotherapy. Various preclinical and a limited number of clinical studies using CAR-NK cells show promising results: efficient elimination of target cells without side effects, such as cytokine release syndrome and neurotoxicity which are seen in CAR-T therapies. In this review, we focus on the details of CAR-NK technology, including the design of efficient and safe CAR constructs and associated NK cell engineering techniques: the vehicles to deliver the CAR-containing transgene, detection methods for CARs, as well as NK cell sources and NK cell expansion. We summarize the current CAR-NK cell literature and include valuable lessons learned from the CAR-T cell field. This review also provides an outlook on how these approaches may transform current clinical products and protocols for cancer treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available